Compare OBAI & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OBAI | PULM |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.2M |
| IPO Year | 2025 | 2013 |
| Metric | OBAI | PULM |
|---|---|---|
| Price | $1.22 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 82.6K | 32.8K |
| Earning Date | 11-13-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.53 | ★ 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,972,000.00 | $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.34 | $67.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.42 | ★ 5069.93 |
| 52 Week Low | $0.13 | $1.06 |
| 52 Week High | $463.16 | $4.94 |
| Indicator | OBAI | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 41.55 |
| Support Level | $0.13 | $1.21 |
| Resistance Level | $2.48 | $1.53 |
| Average True Range (ATR) | 0.27 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 5.96 | 47.77 |
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported many security service requests, emergencies and life-saving interventions. The cloud-based Bond Preventative Personal Security Platform provides users with remote protective services via phone app (using its Bond Preventative Personal Security Platform) and with 24/7 support from its Personal Security Agents, who are in Bond Command Centers and can respond rapidly. It offers distinct services through its phone app (the Bond App) and fully automated Bond Command Centers. Geographically, the company operates in Israel, France, and United States. It derives maximum revenue from United States.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).